UPPSALA, SE / ACCESS Newswire / July 16, 2026 / Senzime AB's (publ) (STO:SEZI)(OTCQX:SNZZF) interim report for April - June (Q2) 2026 is now available on the company's website www.senzime.com.
Financial information Q2 2026:
Net sales amounted to TSEK 24,671 (25,695), a decrease of 4%
Currency-adjusted net sales decreased by 1%
Sales in the US amounted to TSEK 18,716 (19,930), a decrease of 6%
Sales in the International markets amounted to TSEK 5,955 (5,765), an increase of 3%
Gross margin before depreciation amounted to 65.7% (61.8)
Operating costs amounted to TSEK 34,201 (40,207)
Operating profit before depreciation amounted to TSEK -17,267 (-23,573)
Results after financial items amounted to TSEK -21,385 (-34,159)
Earnings per share amounted to SEK -0.14 (-0.24)
Cash and cash equivalents as of June 30th amounted to TSEK 37,112 (132,162)
Financial information first half of 2026:
Net sales amounted to TSEK 47,904 (49,195), a decrease of 3%
Currency-adjusted net sales increased by 4%
Sales in the US amounted to TSEK 33,591 (35,481), a decrease of 6%
Sales in the International markets amounted to TSEK 14,383 (13,714), an increase of 5%
Gross margin before depreciation amounted to 64.4% (63.8)
Operating costs amounted to TSEK 69,763 (77,504)
Operating profit before depreciation amounted to TSEK -37,469 (-44,411)
Results after financial items amounted to TSEK -44,627 (-69,981)
Earnings per share amounted to SEK -0.28 (-0.50)
Philip Siberg, CEO, comments:
Sensor sales continued their strong momentum, driven by expanding utilization of TetraGraph systems in the market. While U.S. hospital hardware market conditions remained challenging during the second quarter, we have increased our focus on operational fundamentals resulting in improved margins, a further reduction in our cost base, and a significantly strengthened cash flow. Our objective of reaching profitability within Q4 remains firmly on track.
As in the first quarter, second-quarter sales were affected by a slower U.S. market, with several expected hospital contracts continuing to see delays. Despite this, we secured several important new agreements during the quarter, underscoring the underlying strength of our commercial pipeline. These included first deliveries to one of the world's largest integrated delivery networks (IDNs), with potential to encompass more than 150 hospitals; an expanded agreement with a leading IDN in the southeastern U.S and a new contract with another top-ranked U.S. children's hospital.
The underlying business continues to develop strongly. Sensor sales increased by 48 percent in local currencies. Recurring sensor sales now account for approximately 80 percent of our revenue, reflecting the continued increase in utilization of TetraGraph systems across our approximately 750 hospital customers worldwide.